What is new . . . .

• SAJDVD Volume 9, Issue 1 is now available to be viewed online via our new eJournal publication viewer »
  Articles include:
  New antithrombotic drugs
  Anticoagulation in diabetic patients
  Gliptins in type 2 diabetes
  Risk of cardiovascular disease in the Bellville pilot study
  Serum levels of RAGE and TNF-α in type 2 diabetes
  Serum tumour necrosis factor-α in type 2 diabetes
  Improving warfarin control
  Liraglutide: an incretin mimetic
   
• IDF WATCH - 2011 UPDATE FROM DUBAI, UNITED ARAB EMIRATES
  In keeping with previous International Diabetes Federation congresses, the Dubai meeting presented an exciting and varied series of lectures and symposia. This paralleled the diverse and unique architecture of the city. Read more »
   
• Sanofi-Aventis specialist diabetes meeting, Cape Town
  In a new direction for Sanofi-Aventis, John Fagan, CEO of the South and West African Division, pointed out that not only is diabetes a key focus area for Sanofi, ‘but we also need to go beyond traditional pharmaceutical research and development in our focus.
  
  Together with clinicians, we need to think about the patient first, then about the product, and do competent research and development to meet patients’ unmet needs’, he said. This approach is reflected in the Diabetes Division’s new slogan, ‘Going beyond, together’. Read more »
   
  
• New guidelines recommend lower LDL target in high-risk cardiovascular patients
  The South African Heart Association and the Lipid and Atherosclerosis Society of Southern Africa (LASSA) held their second joint guideline collaboration meeting on 15 and 16 October 2011. The meeting was attended by representatives of both societies, the funding industry and the Department of Health, as well as various medical specialists. Read more »